Market Cap 163.07M
Revenue (ttm) 56.13M
Net Income (ttm) -14.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -26.14%
Debt to Equity Ratio 1.16
Volume 1,598,300
Avg Vol 130,590
Day's Range N/A - N/A
Shares Out 23.30M
Stochastic %K 93%
Beta 0.87
Analysts Strong Sell
Price Target $9.75

Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 480 434 6670
Address:
9237 East Via de Ventura Boulevard, Suite 105, Scottsdale, United States
Tomasini
Tomasini Jun. 27 at 1:56 PM
$DERM stuck on $7 until emrosi news
0 · Reply
T_rader
T_rader Jun. 24 at 6:39 PM
$DERM well timed to get a start in the black. If sales accelerate this could be a good one to hold onto for a few Q’s.
0 · Reply
Dawilfur
Dawilfur Jun. 24 at 5:15 PM
$DERM This is really bullish for $FBIO too, which has FDA approval awaiting. Fortress Biotech and Journey Medical are directly connected: Journey Medical was founded and remains majority-controlled by Fortress Biotech. https://finance.yahoo.com/news/journey-medical-join-russell-2000-123000866.html
0 · Reply
pandodark
pandodark Jun. 24 at 3:25 PM
$DERM With Russel addition, funds will have to buy this now. Should start steady climb. Combined with sales news, very positive.
0 · Reply
Sawnchey
Sawnchey Jun. 24 at 1:43 PM
$DERM Nice to see the addition to the indices today. In practical terms, this does not normally do much for price, BUT this is an absolutely solid company who's biggest problem is that it is overlooked. So the more availability and publicity the better!
0 · Reply
T_rader
T_rader Jun. 23 at 8:23 PM
$DERM added today, still holding the bottom of the 3month MA.
0 · Reply
T_rader
T_rader Jun. 20 at 4:59 PM
$DERM picked up 2k. RSI is getting into the buy zone. Looks like it’s holding the lower channel but may go down more before any volume comes in.
0 · Reply
T_rader
T_rader Jun. 20 at 2:20 PM
$DERM Couldn’t even get shares if I wanted to with this volume
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 12:36 PM
$DERM Journey Medical announces data analysis from Phase 3 trials of Emrosi Journey Medical announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi for the treatment of moderate-to-severe papulopustular rosacea in adults will be presented at the Society of Dermatology Physician Associates 2025 Summer Dermatology Conference taking place June 25-29 in Washington, DC. The analysis determined that differences in body weight did not affect the efficacy of Emrosi in the two Phase 3 trials, which supported its November 2024 FDA approval. Subjects in the double-blind, placebo-controlled Minocycline Versus Oracea in Rosacea-1 and Minocycline Versus Oracea in Rosacea-2 Phase 3 clinical trials were randomized in a 3:3:2 ratio to treatment with Emrosi, doxycycline 40 mg, or placebo once daily for 16 weeks. The coprimary efficacy endpoints were: the proportion of participants demonstrating Investigator's Global Assessment treatment success with Emrosi vs. placebo; and reductions in total inflammatory lesion counts with Emrosi vs. placebo. Comparisons between Emrosi and doxycycline were secondary endpoints. Sub-group analyses were conducted in patients with body weight less than or equal to the median body weight and in patients with body weight greater than the median body weight. Of the 653 participants enrolled, 323 were randomized in MVOR-1 and 330 were randomized in MVOR-2. The median body weight at baseline was 83.5 kg in MVOR-1 and 83.0 kg in MVOR-2. Emrosi showed superior efficacy on both co-primary endpoints, in both the body weight categories, compared to placebo and doxycycline. Emrosi was generally well tolerated, with no notable between-group differences in the frequency or severity of reported adverse events.
0 · Reply
Tomasini
Tomasini Jun. 18 at 4:07 PM
$DERM what manipulation. every time tries to breakout , beaten back down. mms in fraud mode
0 · Reply
Latest News on DERM
Top 3 Health Care Stocks That May Crash In Q2

Apr 7, 2025, 11:23 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Crash In Q2

ALMS CMRX


Tomasini
Tomasini Jun. 27 at 1:56 PM
$DERM stuck on $7 until emrosi news
0 · Reply
T_rader
T_rader Jun. 24 at 6:39 PM
$DERM well timed to get a start in the black. If sales accelerate this could be a good one to hold onto for a few Q’s.
0 · Reply
Dawilfur
Dawilfur Jun. 24 at 5:15 PM
$DERM This is really bullish for $FBIO too, which has FDA approval awaiting. Fortress Biotech and Journey Medical are directly connected: Journey Medical was founded and remains majority-controlled by Fortress Biotech. https://finance.yahoo.com/news/journey-medical-join-russell-2000-123000866.html
0 · Reply
pandodark
pandodark Jun. 24 at 3:25 PM
$DERM With Russel addition, funds will have to buy this now. Should start steady climb. Combined with sales news, very positive.
0 · Reply
Sawnchey
Sawnchey Jun. 24 at 1:43 PM
$DERM Nice to see the addition to the indices today. In practical terms, this does not normally do much for price, BUT this is an absolutely solid company who's biggest problem is that it is overlooked. So the more availability and publicity the better!
0 · Reply
T_rader
T_rader Jun. 23 at 8:23 PM
$DERM added today, still holding the bottom of the 3month MA.
0 · Reply
T_rader
T_rader Jun. 20 at 4:59 PM
$DERM picked up 2k. RSI is getting into the buy zone. Looks like it’s holding the lower channel but may go down more before any volume comes in.
0 · Reply
T_rader
T_rader Jun. 20 at 2:20 PM
$DERM Couldn’t even get shares if I wanted to with this volume
0 · Reply
DonCorleone77
DonCorleone77 Jun. 20 at 12:36 PM
$DERM Journey Medical announces data analysis from Phase 3 trials of Emrosi Journey Medical announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi for the treatment of moderate-to-severe papulopustular rosacea in adults will be presented at the Society of Dermatology Physician Associates 2025 Summer Dermatology Conference taking place June 25-29 in Washington, DC. The analysis determined that differences in body weight did not affect the efficacy of Emrosi in the two Phase 3 trials, which supported its November 2024 FDA approval. Subjects in the double-blind, placebo-controlled Minocycline Versus Oracea in Rosacea-1 and Minocycline Versus Oracea in Rosacea-2 Phase 3 clinical trials were randomized in a 3:3:2 ratio to treatment with Emrosi, doxycycline 40 mg, or placebo once daily for 16 weeks. The coprimary efficacy endpoints were: the proportion of participants demonstrating Investigator's Global Assessment treatment success with Emrosi vs. placebo; and reductions in total inflammatory lesion counts with Emrosi vs. placebo. Comparisons between Emrosi and doxycycline were secondary endpoints. Sub-group analyses were conducted in patients with body weight less than or equal to the median body weight and in patients with body weight greater than the median body weight. Of the 653 participants enrolled, 323 were randomized in MVOR-1 and 330 were randomized in MVOR-2. The median body weight at baseline was 83.5 kg in MVOR-1 and 83.0 kg in MVOR-2. Emrosi showed superior efficacy on both co-primary endpoints, in both the body weight categories, compared to placebo and doxycycline. Emrosi was generally well tolerated, with no notable between-group differences in the frequency or severity of reported adverse events.
0 · Reply
Tomasini
Tomasini Jun. 18 at 4:07 PM
$DERM what manipulation. every time tries to breakout , beaten back down. mms in fraud mode
0 · Reply
Tomasini
Tomasini Jun. 18 at 3:15 PM
$DERM this stock is being manipulated big time by a few traders and mms. creating cheap share opportunities but with risks as long as this continues. need news
0 · Reply
pandodark
pandodark Jun. 18 at 2:18 PM
$DERM So many good things happening but they stay radio silent. More updates would help.
1 · Reply
Tomasini
Tomasini Jun. 17 at 8:06 PM
$DERM wow . $6.31. hard to believe
0 · Reply
Sawnchey
Sawnchey Jun. 16 at 7:43 PM
$DERM The last Ex-US licence deal was for Qbrexza in multiple Asian territories. They recieved an upfront payment roughly the size of 1 Year's sales in the US for the preceding year. With peak sales in the US for Emrosi of 200m, it is not unreasonable to envision a future where Journey inks a deal with an upfront payment larger than its current Market Cap.
1 · Reply
Tomasini
Tomasini Jun. 16 at 2:13 PM
$DERM Dead money
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 15 at 6:54 PM
$DERM Emrosi™ could be the blockbuster that transforms Journey Medical. Learn how this new therapy is capturing investor attention. https://biotechhealthx.com/biotech-news/fda-approved-rosacea-drug-just-changed-the-game-for-journey-medical-derm/
0 · Reply
Tomasini
Tomasini Jun. 12 at 2:13 PM
$DERM i keep buying. now under $7 . a steal imo
0 · Reply
Tomasini
Tomasini Jun. 10 at 2:27 PM
$DERM wow. this stock is dead. no news and no interest. i guess $7 is good deal esp. with black label news on Oracia
0 · Reply
Tomasini
Tomasini Jun. 10 at 2:12 PM
$DERM even if emrosi gets black labeled still best in class on eficacy
0 · Reply
makrodimutross
makrodimutross Jun. 9 at 8:59 PM
$FBIO $FBIOP $DERM If you were on the fence about Emrosi becoming "Standard of Care" due to efficacy alone, now you must be firmly on the right side of the fence due to the new black box warning for Oracea. the L goes to Galderma, and the W to Journey for this one.
0 · Reply
makrodimutross
makrodimutross Jun. 9 at 8:56 PM
$FBIO $FBIOP $DERM https://medshadow.org/fda-side-effects-update-tetracycline-antibiotics-skin-reactions-new-rinvoq-warnings-for-gca/ "Drugs in the tetracycline class now carry updated safety labels warning of a serious skin reaction known as fixed drug eruptions (FDE), a form of hypersensitivity that causes rashes or blistering, typically recurring in the same spot each time the drug is taken. With an FDE reaction, skin rashes or blistering worsen each subsequent time the drug is used. A very severe variant of FDE is “generalized bullous fixed drug eruption” (GBFDE), which can be life-threatening. If severe skin reactions occur, patients are advised to discontinue the medicine immediately and seek medical help. These label changes were made in response to an FDA letter (here is one example) sent in December 2024 notifying drug sponsors that the required safety information should be added to the drug labels. Two of the tetracycline antibiotics in this update (Doryx and Oracia) also have new warnings about psychiatric adverse events."
2 · Reply
Tomasini
Tomasini Jun. 9 at 2:19 PM
$DERM dirt cheap under 7.25
1 · Reply